Neumora Therapeutics, Inc. 8-K

What Happened

• Neumora Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 in a press release dated May 7, 2026. The company filed a Current Report on Form 8-K (Accession No. 0001193125-26-210310) to report these quarterly results; the full press release is furnished as Exhibit 99.1.
• The 8-K was signed on behalf of Neumora by Michael Milligan, Chief Financial Officer, on May 7, 2026.

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: Quarter ended March 31, 2026.
• Press release furnished as Exhibit 99.1 to the Form 8-K (full financial details presented there).
• Form 8-K includes standard interactive XBRL cover page data (Exhibit 104).

Why It Matters

• This filing signals that Neumora has publicly reported its latest quarterly performance — investors should review the furnished press release (Exhibit 99.1) for revenue, profit/loss, cash position, R&D spending, and any forward-looking commentary or guidance.
• Quarterly results can affect near-term stock performance and help investors evaluate progress against clinical and development milestones; the 8-K provides the official, timely disclosure required under securities rules.